%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.Analyst Target
Analyst consensus price target: $1.50.What is Scienture Holdings, Inc.?
operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
SCNX · Verdict
Moderate reward · elevated risk
SCNX's standout is volatility; balance sheet and profitability weigh on the picture.
Based on 88% data coverage
SCNX · Verdict
What’s working & what to watch
Strengths 1
- Volatility95/100
Top decile vs peers
Watchouts 3
- Balance sheet6/100
Current ratio 0.80
- Profitability28/100
6635% net margin · -24% ROE
- Cash flow35/100
-10449% free-cash-flow margin
Model-based scoring. For information only — not financial advice.
What is Scienture Holdings, Inc.?
operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 17.48M, and a P/E ratio of 0.6x.
Financial Highlights
Investment Breakdown
Analysis
Reward: Moderate (51)The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.